Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Remidex manufactures micronutrient premixes and nutraceuticals,
The revenues this quarter are in line with the outlook we envisaged for the year
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
EBITDA margins expand to 31.3%
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Subscribe To Our Newsletter & Stay Updated
